Icit Inc

TAS::89 0328::TAS RECOVERY - SGIG 09-0340:THE WESTERN INTERCONNECTION SYNCHROPHASOR PROJECT (WISP) WILL DESIGN AND IMPLEMENT A WIDE-AREA COMMUNICATIO

TAS::89 0328::TAS RECOVERY ACT NEW AWARD-RESOURCE ASSESSMENT AND INTERCONNECTION-LEVEL TRANSMISSION ANALYSIS AND PLANNING TO WESTERN ELECTRICITY COOR

THE NATIONAL RESOURCE CENTER ON AD/HD: A PROGRAM OF CHADD

ADDUCT DIPSTICK FOR DIAGNOSIS OF ACETAMINOPHEN TOXICITY

IMPLEMENTING EVIDENCE-BASED HEALTH PROMOTION PROGRAMS FOR CHILDREN WITH ATTENTION DEFICIT/HYPERACTIVITY DISORDER

FERTILIZER PRODUCTION EXPANSION PROGRAM

ACETASTAT VALIDATION AND COMMERCIALIZATION - JAMES, LAURA P PROJECT SUMMARY/ABSTRACT ACETAMINOPHEN (APAP) IS THE MOST COMMON DRUG USED FOR THE TREATMENT OF PAIN AND FEVER AROUND THE WORLD. IT IS ALSO THE MOST COMMON CAUSE OF LIFE THREATENING DRUG-INDUCED LIVER DAMAGE. UNFORTUNATELY, PHYSICIANS HAVE NO SPECIFIC TEST AVAILABLE TO THEM TO CONFIRM THE DIAGNOSIS OF APAP LIVER INJURY. CURRENTLY, PHYSICIANS RELY ON PATIENT HISTORY AND NON-SPECIFIC TESTS OF LIVER INJURY WHEN EVALUATING PATIENTS WITH LIVER INJURY DUE TO APAP. ACETAMINOPHEN TOXICITY DIAGNOSTICS, LLC HAS DEVELOPED A RAPID LATERAL FLOW IMMUNOASSAY THAT CAN DETECT APAP LIVER INJURY. OUR TEST, KNOWN AS ACETASTAT, IS FAST, EASY AND SPECIFIC TO APAP LIVER INJURY. OUR PLANS FOR THIS COMMERCIALIZATION READINESS PROGRAM PROPOSAL INCLUDE OPTIMIZING ACETASTAT IN A COLLABORATION WITH DCN DIAGNOSTICS. SECONDLY, WE WILL PRODUCE ACETASTAT ACCORDING TO CURRENT GOOD MANUFACTURING PRACTICE (CGMP). FINALLY, WE WILL COMPLETE IN VITRO VALIDATION STUDIES AND PERFORM A MULTI-SITE CLINICAL TRIAL TO EXAMINE THE CLINICAL PERFORMANCE OF ACETASTAT. THESE EFFORTS WILL SUPPORT THE SUBMISSION OF A DE NOVO APPLICATION TO THE FOOD AND DRUG ADMINISTRATION FOR CLEARANCE FOR SALES OF ACETASTAT IN THE US. ULTIMATELY, ACETASTAT WILL EXPEDITE AND SIMPLIFY THE DIAGNOSIS OF APAP LIVER INJURY, PROMPTING MORE RAPID TREATMENT, AND SAVING LIVES. OMB NO. 0925-0001/0002 (REV. 03/2020 APPROVED THROUGH 02/28/2023) PAGE 1

DD15-1505-NATIONAL PUBLIC HEALTH PRACTICE AND RESOURCE CENTERS FOR CHILDREN WITH ATTENTION DEFICIT/H

PLASTICITY-BASED ADAPTIVE COGNITIVE REMEDIATION FOR SCHIZOPHRENIA

PLASTICITY-BASED ADAPTIVE COGNITIVE REMEDIATION (PACR) FOR OIF/OEF VETERANS: A RANDOMIZED CONTROLLED TRIAL

IMPLEMENTING EVIDENCE-BASED HEALTH PROMOTION PROGRAMS FOR ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD) - ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) IS A NEURODEVELOPMENTAL DISORDER THAT IS USUALLY FIRST DIAGNOSED IN CHILDHOOD AND OFTEN CONTINUES INTO ADULTHOOD. IT CAN LEAD TO SERIOUS PROBLEMS, INCLUDING POOR RELATIONSHIPS, FAMILY STRESS, MISBEHAVIOR, PROBLEMS AT SCHOOL, JOB FAILURE, OBESITY, AND AN INCREASED RISK FOR ACCIDENTAL INJURIES. INFORMATION AND EDUCATION ON ADHD THAT IS BASED ON BEST EVIDENCE IS KEY TO PROPERLY MANAGING ADHD. CHADD, INC. (CHILDREN AND ADULTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER) IS THE NATION’S LEADING NONPROFIT ORGANIZATION DEDICATED TO IMPROVING THE LIVES OF CHILDREN, ADULTS, AND FAMILIES AFFECTED BY ADHD. SINCE 2002, CHADD’S NATIONAL RESOURCE CENTER ON ADHD (NRC) HAS SERVED AS THE CLEARINGHOUSE FOR EVIDENCE-BASED INFORMATION ON ADHD, SUPPORTING INDIVIDUALS WITH THE DISORDER, THEIR FAMILIES, AND THE HEALTHCARE PROVIDERS AND EDUCATORS INVOLVED IN THEIR LIVES. CHADD’S NRC PROPOSES TO IMPLEMENT EVIDENCE-BASED HEALTH PROMOTION PROGRAMS FOR ADHD. THE STRATEGIES AND ACTIVITIES OF THESE PROGRAMS WILL IDENTIFY THE NEEDS THAT INDIVIDUALS WITH ADHD, THEIR FAMILIES, HEALTHCARE PROVIDERS, AND EDUCATORS HAVE FOR MANAGING ADHD. CHADD’S NRC WILL MEET THESE NEEDS BY CREATING COMMUNICATION AND EDUCATION PROGRAMS, PRODUCTS, TOOLS AND SUPPORTS THAT ARE BASED ON RELIABLE EVIDENCE AND ARE APPROPRIATE FOR EACH OF THE AUDIENCES. SINCE ADHD EXISTS FOR ALL RACES, ETHNICITIES, AND IN ALL GEOGRAPHIC AREAS, THE PROGRAMS WILL REACH OUT TO A DIVERSE AUDIENCE, ESPECIALLY TO THE COMMUNITIES AFFECTED BY HEALTH AND EDUCATIONAL DISPARITIES. FOR INDIVIDUALS WITH ADHD, THEIR FAMILIES, AND COMMUNITIES, THE PROGRAMS WILL IMPROVE THEIR ACCESS TO RELIABLE INFORMATION, SUPPORT, AND SERVICES THAT WILL IMPROVE THEIR LIVES. THE PROGRAMS WILL PROVIDE EDUCATION, TRAINING, AND SUPPORT TO HEALTHCARE PROVIDERS SO THAT THEY CAN PROPERLY DIAGNOSE AND TREAT PEOPLE WITH ADHD. EDUCATORS WILL BE PROVIDED WITH EDUCATION AND TRAINING SO THAT THEY WILL USE EVIDENCE-BASED TEACHING STRATEGIES TO HELP THEIR STUDENTS WITH ADHD SUCCEED IN SCHOOL. CHADD’S RESIDENT EXPERT AND PROFESSIONAL ADVISORY BOARD MEMBERS WILL REVIEW THE SCIENTIFIC EVIDENCE FOR ALL THE EDUCATIONAL RESOURCES THAT ARE DEVELOPED. CHADD WILL COLLABORATE WITH THE CDC TO MEET PROGRAM GOALS AND SUPPORT CDC’S INTERESTS. CHADD WILL ALSO COLLABORATE WITH VARIOUS ADHD EXPERTS AND PROFESSIONAL GROUPS, INCLUDING THE ANNUAL INTERNATIONAL CONFERENCE ON ADHD ORGANIZING COMMITTEE, TO DEVELOP EDUCATION AND TRAINING PROGRAMS FOR HEALTHCARE PROVIDERS AND EDUCATORS. CHADD’S ADHD COMMUNITIES TOGETHER (ACT) PROGRAM WILL CONTINUE TO REACH RACIAL, ETHNIC, AND RURAL COMMUNITIES THROUGH NEW AND EXISTING COLLABORATIONS. TO INCREASE DISSEMINATION OF PROGRAM MATERIALS, CHADD WILL COLLABORATE WITH OTHER MENTAL HEALTH AND EDUCATOR ASSOCIATIONS. CHADD’S SUPPORT GROUPS, SPECIFICALLY THE CHADD REGIONAL CENTERS, WILL COLLABORATE WITH PUBLIC AND PRIVATE SECTORS, INCLUDING BUSINESSES, PROFESSIONAL ASSOCIATIONS, UNIVERSITIES, SCHOOL SYSTEMS, AND OTHER CONCERNED GROUPS WITHIN THEIR COMMUNITIES. PROGRAM ACTIVITIES WILL BE WIDELY PUBLICIZED ON SOCIAL MEDIA PLATFORMS, WEBSITE, AND NEWSLETTERS. THEY WILL BE EVALUATED THROUGHOUT THE YEAR TO IMPROVE PROCESSES AND DEVELOP NEW MATERIALS AND PROGRAMS WHEN AND WHERE THEY ARE NEEDED.

THE NPHPRC DEVELOPS AND PROVIDES HEALTH PROMOTION PROGRAMS AND HEALTH COMMUNICATI

COMPUTERIZED SOCIAL COGNITION TRAINING FOR SCHIZOPHRENIA

SBIR PHASE II: TELE-DIRECTED ARTIFICIALLY INTELLIGENT SONOGRAPHY ROBOT -THE BROADER/COMMERCIAL IMPACT OF THIS SMALL BUSINESS INNOVATION RESEARCH (SBIR) PHASE II PROJECT IS TO CREATE A TELEROBOTIC SYSTEM FOR THE ADMINISTRATION OF SONOGRAPHS, WITH AN INITIAL FOCUS ON ECHOCARDIOGRAMS. THE WAIT TIMES FOR ECHOCARDIOGRAMS CAN BE UPWARDS OF 12 WEEKS WITH APPROXIMATELY 7 MILLION PERFORMED ANNUALLY IN THE U.S. THIS ISSUE IS COMPOUNDED BY A NATIONWIDE SHORTAGE OF SONOGRAPHERS, DISPARITIES IN THE DISTRIBUTION OF THESE PROFESSIONALS, AND HIGH BURNOUT RATES LINKED TO WORKPLACE INJURIES FROM REPETITIVE TASKS. AN ECHOCARDIOGRAM IS THE FIRST LINE OF CARE FOR PATIENTS PRESENTING WITH ACUTE SYMPTOMS SUGGESTIVE OF SOME LIFE THREATENING CONDITIONS. THESE INCLUDE MYOCARDIAL INFARCTION, ACUTE VALVULAR REGURGITATION, STENOSIS, CARDIAC TAMPONADE, CONGESTIVE HEART FAILURE, CEREBROVASCULAR ACCIDENT (?STROKE?), ENDOCARDITIS, PERICARDITIS, LIFE THREATENING ARRHYTHMIAS, AND MYOCARDITIS. 1. INCREASES THE THROUGHPUT PER SONOGRAPHER BY ENABLING SIMULTANEOUS SUPERVISION OF DATA ACQUISITION, 2.REDUCES WORKPLACE INJURIES THAT SHORTEN CARDIAC SONOGRAPHERS? CAREERS, AND 3. REDUCES THE NEED FOR A COLLOCATED WORKFORCE OF SPECIALIZED SKILL SETS AND THEREBY INCREASING ACCESS TO CARE. IN THE UNITED STATES, HEART DISEASE IS THE LEADING CAUSE OF DEATH KILLING ONE PERSON EVERY 33 SECONDS. THE FIRST STEP TO HELP SOLVE THIS PROBLEM IS FAST ACCESS TO DIAGNOSTIC IMAGING SUCH AS ECHOCARDIOGRAMS. THIS SMALL BUSINESS INNOVATION RESEARCH (SBIR) PHASE II PROJECT BUILDING UPON PHASE I RESULTS THAT SHOWED THE CAPABILITY OF THE ROBOTIC SYSTEM TO CAPTURE HIGH-QUALITY IMAGES FROM A SINGLE TRANSTHORACIC ECHOCARDIOGRAM (TTE) VIEW USING MACHINE VISION TO IDENTIFY PROPER PROBE DEPLOYMENT ON THE BODY AND USING ROBOTIC CONTROLS TO SAFELY MOVE THE PROBE WITHOUT SURPASSING SAFE PRESSURE THRESHOLDS NOR LOSING CONTACT WITH THE SKIN. PHASE II WILL BUILD UPON THIS ROBUST FOUNDATION, AIMING TO VALIDATE AND BROADEN THE TECHNOLOGY'S CAPABILITIES TO MEET THE EXACTING STANDARDS OF OUR CUSTOMERS. THE PROJECT WILL FURTHER DEVELOP THE ROBOT'S IMAGING PROFICIENCY TO COVER THE COMPLETE ECHOCARDIOGRAM PROTOCOL INCLUDING THE PARASTERNAL LONG AXIS (PLAX), PARASTERNAL SHORT AXIS (PSAX), APICAL VIEWS, SUBCOSTAL VIEW, AND SUPRASTERNAL NOTCH VIEW. THE PROJECT WILL ALSO IMPROVE USABILITY ACROSS DIVERSE PATIENT DEMOGRAPHICS AND VALIDATE ITS PERFORMANCE AND USABILITY IN REAL-WORLD CLINICAL SETTINGS. ADDITIONALLY, WE PLAN TO EXPLORE THE TECHNOLOGY'S APPLICATION TO OTHER ULTRASOUND PROCEDURES PERFORMED ON THE ABDOMEN, ESTABLISHING THE TRANSFORMATIONAL AND PLATFORM POTENTIAL OF THE TECHNOLOGY. THE PROJECT ALIGNS WITH THE NSF'S MISSION TO PROPEL HEALTH AND WELFARE FORWARD THROUGH TECHNOLOGICAL BREAKTHROUGHS, SETTING THE STAGE FOR THE U.S. TO LEAD IN THE GLOBAL ARENA OF DIAGNOSTIC IMAGING INNOVATION. THIS AWARD REFLECTS NSF'S STATUTORY MISSION AND HAS BEEN DEEMED WORTHY OF SUPPORT THROUGH EVALUATION USING THE FOUNDATION'S INTELLECTUAL MERIT AND BROADER IMPACTS REVIEW CRITERIA.- SUBAWARDS ARE NOT PLANNED FOR THIS AWARD.

PLASTICITY-BASED ADAPTIVE COGNITIVE REMEDIATION PROGRAM (PACR) FOR THE TREATMENT

TONIC AND PHASIC ALERTNESS TRAINING FOR THE TREATMENT OF HEMINEGLECT

1954-1720 NITRICITY INC. PROJECT TITLE: NON-EQUILIBRIUM PLASMA FOR ENERGY-EFFICIENT NITROGEN FIXATION FOA NUMBER DE-FOA-0001954 SOLICITATIONS ON TOPICS INFORMING NEW PROGRAM AREAS SBIR/STTR-SUPPORTING ENTREPRENEURIAL ENERGY DISCOVERIES (SEED SBIR/STTR) THE PURPOSE OF THIS AWARD IS TO PROVIDE FUNDS TO NITRICITY, INC. TO DEVELOP A TECHNOLOGY THAT PRODUCES NITROGEN FERTILIZER USING INPUTS OF AIR, WATER, AND RENEWABLE ELECTRICITY.

TONIC AND PHASIC ALERTNESS TRAINING FOR COGNITIVE DECLINE IN AGING

**AWARDS ISSUED PRIOR TO JANUARY 20, 2025, WERE FUNDED UNDER PREVIOUS ADMINISTRATIONS AND MAY NOT REFLECT THE PRIORITIES AND POLICIES OF THE CURRENT ADMINISTRATION.** HEAT INTEGRATION OF PLASMA REACTORS FOR ELECTRIFIED FERTILIZER PRODUCTION

OREXIN RECEPTOR AGONISTS FOR THE TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS AND CA

COMPUTERIZED PLASTICITY-BASED TRAINING TO REMEDIATE DEFICITS IN SOCIAL COGNITION

DIPSTICK ASSAY FOR DETECTION OF ACETAMINOPHEN PROTEIN ADDUCTS

CREATING A NEW ASSISTANCE AGREEMENT FOR NORTHWEST SBTRC FROM REQUISITION

ENFORCING UNDERAGE DRINKING LAWS PROGRAM (EUDL)

SBIR PHASE I: TELE-DIRECTED ARTIFICIALLY INTELLIGENT MEDICAL ROBOT -THE BROADER IMPACT/COMMERCIAL POTENTIAL OF THIS PHASE I PROJECT IS TO DEVELOP A NOVEL ARTIFICIAL-INTELLIGENCE (AI) ROBOT-CONTROL PARADIGM TO FACILITATE REAL-TIME TELE-ROBOTICS AND ADVANCE HUMANKIND?S ROBOTIC CAPABILITY. THIS AI CONSTANTLY INTERPRETS THE INTENT OF THE OPERATOR IN THE CONTEXT OF THE ROBOT?S ENVIRONMENT, AND MAKES REAL-TIME ADJUSTMENTS TO THE MOTION OF THE ROBOT TO ACCOMPLISH THE INTENDED TASK. ULTIMATELY, THIS ALLOWS THE OPERATOR TO FOCUS ON THE OBJECTIVE INSTEAD OF OPERATING THE ROBOT. THIS PROJECT WILL ALLOW TELE-ROBOTICS TO BECOME A VIABLE SOLUTION IN UNCERTAIN ENVIRONMENTS WHERE TRADITIONAL CONTROL SCHEMES, WITH INHERENT LATENCY AND PRECISION ISSUES, CURRENTLY PREVENT ADOPTION OF ROBOTIC SOLUTIONS. THIS BENEFITS APPLICATIONS IN WHICH A HIGHER DEGREE OF EXPERTISE AND DECISION-MAKING IS REQUIRED TO PERFORM TASKS IN A DANGEROUS OR INACCESSIBLE LOCATION. THE FIRST APPLICATION OF THIS TECHNOLOGY WILL ALLOW NURSES TO PROVIDE PATIENT CARE WITHIN HOSPITAL ISOLATION ENVIRONMENTS TO PREVENT EXPOSURE TO THE PATIENT AND CARE-PROVIDERS. ADDITIONAL APPLICATIONS INCLUDE MILITARY, INDUSTRIAL MAINTENANCE, AEROSPACE, PUBLIC SAFETY, ENERGY, MINING, AND UNDERSEA SOLUTIONS. TELE-ROBOTICS IS A $62B MARKET IN 2019 GROWING BY 13.5% ANNUALLY. THIS SMALL BUSINESS INNOVATION RESEARCH (SBIR) PHASE I PROJECT PROPOSES TO ADDRESS THE NURSING CRISIS WITH AN AI-ENHANCED ROBOTIC IN PATIENT-ISOLATION ENVIRONMENTS. INSTEAD OF DELAYING CARE TO DON AND DOFF PERSONAL-PROTECTIVE EQUIPMENT, NURSES CAN INSTANTLY WORK THROUGH THE EYES, EARS, AND ARMS OF THESE ROBOTS. THE KEY INNOVATION IN THIS PHASE I PROJECT IS NOVEL AI WHICH WILL INTUIT THE INTENT OF THE OPERATOR TO SUCCESSFULLY COMPLETE TASKS. THE PROPOSED RESEARCH WILL DEVELOP A ROBOT CONTROL POLICY WHICH OBSERVES THE ROBOT?S CURRENT ENVIRONMENT AS WELL AS THE USERS CONTROL INPUTS, AND ACTUATES A ROBOT TO ACHIEVE THE DESIRED TASK. THE ROBOT WILL SELF-CORRECT FOR ERRORS MADE BY THE USER THROUGH AN UNDERSTANDING OF THE DESIRED OUTCOMES. AT THE END OF THIS PHASE I PROJECT, WE EXPECT THE ROBOT TO PERFORM A DEMONSTRATION OF ACCURATE AND TIMELY OBJECT MANIPULATION WHILE CONTROLLED BY A REMOTE OPERATOR WITHOUT LINE OF SIGHT TO THE WORK AREA. IN A SUBSEQUENT PHASE, THE ULTIMATE TECHNICAL OBJECTIVE IS FOR THE SOLUTION TO BE AS INTUITIVE AND INVALUABLE AS A MODERN SMARTPHONE. THE BUSINESS OBJECTIVE, DEVELOPED IN PARTNERSHIP WITH HEALTHCARE SYSTEMS, IS TO PROVIDE BETTER ISOLATION-PATIENT OUTCOMES WHILE IMPROVING PRODUCTIVITY AND REDUCING HEALTH RISK FOR NURSES. THIS AWARD REFLECTS NSF'S STATUTORY MISSION AND HAS BEEN DEEMED WORTHY OF SUPPORT THROUGH EVALUATION USING THE FOUNDATION'S INTELLECTUAL MERIT AND BROADER IMPACTS REVIEW CRITERIA.

SBIR PHASE I: ENABLING ON-SITE NITRATE FERTILIZER PRODUCTION: AN ABSORPTION UNIT TO EFFICIENTLY AND SELECTIVELY CAPTURE NITRATES

TAS::89 0318::TAS BALANCING AUTHORITY COOPERATION CONCEPTS TO REDUCE VARIABLE GENERATION INTEGRATION COSTS IN THE WESTERN INTERCONNECTION

AI-ENABLED STROKE PREDICTION IN PATIENTS WITH CHRONIC KIDNEY DISEASE - PROJECT SUMMARY CHRONIC KIDNEY DISEASE (CKD) AFFECTS 14% OF THE U.S. POPULATION AND IS ASSOCIATED WITH A HIGH RISK OF BOTH ISCHEMIC AND HEMORRHAGIC STROKES AND A MORTALITY RATE OF UP TO THREE TIMES THAT OF THE GENERAL POPULATION. EFFECTIVE STROKE RISK PREDICTION IS FLAWED IN CKD PATIENTS, BECAUSE 1) COMORBIDITIES OFTEN REMAIN UNDIAGNOSED, 2) STROKE RISK STRATIFICATION SCHEMES DO NOT CONSIDER STAGES OF CKD, AND 3) THE DETECTION OF STROKE RISK VARIATIONS DUE TO DIALYSIS REQUIRES REAL-TIME RISK MONITORING, WHICH IS UNAVAILABLE TO DATE. THE REAL-TIME MONITORING OF THE STROKE RISK IN CKD PATIENTS, AND IN PARTICULAR FOR THOSE UNDERGOING DIALYSIS, IS LIKELY TO INFLUENCE ADOPTED THERAPEUTIC STRATEGIES AND PROMOTE A MORE PERSONALIZED THERAPEUTIC APPROACH. BETTER CARE AND PREVENTION THROUGH MONITORING OF THESE HIGH-RISK PATIENTS WILL REDUCE MORTALITY RATES AND THEIR HIGH PER CAPITA COST, WHICH IS FIVE TIMES HIGHER THAN THE AVERAGE HEALTHCARE SPENDING. BIOTRICITY IS DEVELOPING BIOFLUX-AI, AN INNOVATIVE SYSTEM FOR REAL-TIME MONITORING AND PREDICTION OF STROKE EPISODES IN CKD PATIENTS. BIOFLUX-AI COMBINES AN FDA-APPROVED, HIGH-PRECISION, SMALL MOBILE CARDIAC TELEMETRY (MCT) DEVICE WITH AI-DRIVEN ALGORITHMS SPECIFICALLY TRAINED FOR THE PREDICTION OF STROKE IN STAGE 4 AND 5 CKD PATIENTS. BIOTRICITY HAS PREVIOUSLY GENERATED AND VALIDATED ALGORITHMS FOR THE AUTOMATED DETECTION OF ECG ABNORMALITIES, INCLUDING ATRIAL FIBRILLATION (AF). GIVEN THE STRONG ASSOCIATION OF AF WITH INCREASED RISK OF BLOOD CLOT FORMATION AND HENCE, ISCHEMIC STROKE IN CKD PATIENTS, BIOTRICITY PROPOSES TO COMBINE THE DETECTION OF THIS ARRHYTHMIA WITH OTHER STROKE RISK FACTORS OF CKD PATIENTS (AGE, WEIGHT, HEIGHT, BMI, CKD STATUS, DIABETES, HEART DISEASE) AND ECG PARAMETERS TO PREDICT STROKE RISK IN REAL-TIME. TO THIS AIM, IN THIS SBIR PHASE I PROJECT A CONVOLUTIONAL NEURAL NETWORK ALGORITHM, WHICH WILL INCORPORATE ALL THESE RISK FACTORS, WILL BE DEVELOPED, TRAINED AND VALIDATED. THE ACCOMPLISHMENT OF THIS FEASIBILITY STUDY WILL PAVE THE ROAD FOR FURTHER DEVELOPMENT AND OPTIMIZATION OF THE AI-BASED ALGORITHM FOR STROKE PREDICTION IN CKD PATIENTS, WHILE WIDENING THE APPLICATION TO A LARGER PATIENT DEMOGRAPHIC, VALIDATING THE PREDICTIVE ALGORITHM FOR PATIENTS WITH OTHER CHRONIC DISEASES.

DEVELOPMENT OF A PHARMACOPROTECTOR FOR PLATINUM TOXICITIES

SBIR PHASE I: A SYSTEM FOR AUTOMATING END-TO-END CREATION OF NATURAL LANGUAGE INTERFACES

A TRANSPORTER PLATFORM TECHNOLOGY FOR DISCOVERY OF DRUGS TO TREAT AUTOIMMUNE DISEASE

DEVELOPMENT OF TRANSPORTER TARGETED PLATINUM DRUGS FOR GLIOBLASTOMA

DEVELOPMENT OF TRANSPORTER TARGETED PLATINUM DRUGS FOR PEDIATRIC TUMOR

THE NASA INNOVATIVE ADVANCED CONCEPTS (NIAC) PROGRAM FOCUSES ON EARLY-STAGE FEASIBILITY STUDIES OF VISIONARY CONCEPTS THAT ADDRESS NATIONAL GOVERNMENT AND COMMERCIAL AEROSPACE GOALS. CONCEPTS ARE SOLICITED FROM ANY FIELD OF STUDY THAT OFFERS A RADICALLY DIFFERENT APPROACH OR DISRUPTIVE INNOVATION THAT MAY SIGNIFICANTLY ENHANCE OR ENABLE NEW HUMAN OR ROBOTIC SCIENCE AND EXPLORATION MISSIONS. THE NIAC PROGRAM SEEKS EXCITING UNEXPLORED CREDIBLE AEROSPACE CONCEPTS WITH AT LEAST ONE MISSION APPLICATION THAT ADDRESSES NASA GOALS OR OFFERS WIDER BENEFITS WITH SPACE OR AERONAUTICS APPLICATIONS. NIAC FOCUSES ON EARLY STUDIES OF VISIONARY AEROSPACE CONCEPTS. THESE AEROSPACE ARCHITECTURES PROPOSED IN THE CONTEXT OF A REPRESENTATIVE MISSION WILL GENERALLY ADVANCE FROM TECHNOLOGY READINESS LEVEL (TRL) 1-2 IN MATURITY AND ARE AIMED TEN OR MORE YEARS IN THE FUTURE.

DEVELOPMENT OF TRANSPORTER TARGETED PLATINUM DRUGS FOR NEUROBLASTOMA

DRUG TRANSPORTERS IN FARM ANIMALS

SBIR PHASE I: A DOUBLE SIDED INCREMENTAL FORMING SYSTEM FOR RAPID DIELESS SHEET METAL FABRICATION

THIS EDA INVESTMENT SUPPORTS THE ELECTRICITIES OF NORTH CAROLINA, INC. WITH PROVIDING TECHNICAL ASSISTANCE TO TEN ECONOMICALLY DISTRESSED PUBLIC POWER COMMUNITIES ACROSS THE STATE OF NORTH CAROLINA TO STRATEGICALLY LEVERAGE MANUFACTURING INVESTMENT OPPORTUNITIES THAT WILL STRENGTHEN LOCAL AND REGIONAL ECONOMIC RECOVERY FROM THE COVID-19 PANDEMIC. ONCE COMPLETED, THE PROJECT WILL HELP ADVANCE LONG TERM ECONOMIC VITALITY AND SUSTAINABILITY, BOLSTER JOB CREATION, AND LEAD TO THE CAPITALIZATION ON NEW OPPORTUNITIES THROUGHOUT THE REGION.

PRESERVATION OF ANCIENT MOSAICS AND OTHER REMAINS FROM THE HELLENISTIC, ROMAN, AND BYZANTINE PERIODS AT HERACLEA LYNCESTIS ARCHAEOLOGICAL SITE.

CONSERVATION OF THE 11TH-12TH-CENTURY MONASTERY OF THE HOLY MOTHER OF GOD ELEUSA IN VELJUSA.

INTESTINAL DRUG TRANSPORTERS IN VETERINARY ANIMALS - INTESTINAL DRUG TRANSPORTERS IN VETERINARY ANIMALS INTESTINAL TRANSPORTERS IN THE ATP BINDING CASSETTE FAMILY (ABC) REDUCE THE ABSORPTION OF MANY XENOBIOTICS INCLUDING PRESCRIPTION DRUGS. ABCG2 ENCODES BCRP, AN IMPORTANT TRANSPORTER THAT IS HIGHLY EXPRESSED IN THE INTESTINE AS WELL AS OTHER BARRIER TISSUES SUCH AS THE BLOOD BRAIN BARRIER. BCRP LIMITS THE ORAL BIOAVAILABILITY OF ITS SUBSTRATES AND THEREFORE CANDIDATE DRUGS THAT ARE FOUND TO HIGHLY INTERACT WITH BCRP ARE OFTEN DISCARDED DURING DRUG DEVELOPMENT. ONLY THOSE WITH LIMITED OR NO INTERACTIONS WITH BCRP ARE SELECTED FOR FURTHER DEVELOPMENT. HOWEVER, FOR VETERINARY DRUG DEVELOPMENT, CELL LINES EXPRESSING THE APPROPRIATE SPECIES ORTHOLOGS OF BCRP ARE NOT AVAILABLE. SINCE SPECIES DIFFERENCES IN THE SUBSTRATE AND INHIBITOR SELECTIVITY OF TRANSPORTERS ARE LIKELY TO OCCUR, THE LACK OF CELL LINES EXPRESSING SPECIES ORTHOLOGS OF TRANSPORTERS REPRESENTS AN ENORMOUS GAP FOR VETERINARY DRUG DEVELOPMENT. THE GOALS OF THIS PHASE I SBIR RESEARCH ARE TO CREATE AND CHARACTERIZE CELL LINES AND YEAST STRAINS STABLY EXPRESSING VETERINARY ANIMAL BCRP FROM DOG, CAT, SHEEP AND PIG. THE CELL LINES AND YEAST STRAINS WILL SERVE AS RESOURCES FOR DRUG DEVELOPERS, AND WILL REPRESENT INNOVATIVE “ALTERNATIVE METHODS, IN SUPPORT OF REPLACEMENT/REDUCTION/REFINEMENT FOR ACTIVITIES INVOLVING ANIMAL RESEARCH.” IN STUDIES UNDER AIM 1, WE WILL CREATE STABLE CELL LINES AND YEAST STRAINS EXPRESSING THE SPECIES ORTHOLOGS OF BCRP. IN AIM 2, WE WILL CREATE ROBUST ASSAYS AND USE MODEL SUBSTRATES AND INHIBITORS OF BCRP TO CHARACTERIZE SPECIES DIFFERENCES IN THE SUBSTRATE AND INHIBITOR SPECIFICITY OF THE TRANSPORTER. METHODS USED IN THE PROPOSED STUDIES INCLUDE TECHNOLOGIES FOR CREATION OF CELL LINES STABLY EXPRESSING THE TRANSPORTER ORTHOLOGS, AND ISOTOPIC UPTAKE AND FLUX ASSAYS IN CELLS. YEAST TRANSFORMATION PROCEDURES AND CYTOTOXICITY ASSAYS WILL ALSO BE APPLIED. COLLECTIVELY THESE STUDIES WILL ENABLE VETERINARY DRUG DEVELOPMENT BY PROVIDING MUCH NEEDED CELL LINES FOR PREDICTING DRUG ABSORPTION. THE CELL LINES WILL REDUCE THE RELIANCE ON TRIAL-AND-ERROR EXPERIMENTAL APPROACHES IN ANIMALS.

LOW-COST PLASMA REACTORS FOR ON-FARM NITROGEN FIXATION

OMNICITY: JOINING CIRCLES ACADEMIC-COMMUNITY PARTNERSHIP CONFERENCE SERIES

TAS::57 3600::TAS"SCALABLE PHOTONIC MACHINE FOR NEUROMORPHIC COMPUTATION-COMPUTATIONAL COGNITION"

COMMUNITY FACILITY GRANTS

RBDG RURAL BUSINESS COOP RURAL ENTERPRISE GRANT

THIS PROGRAM IS A U.S.-TANZANIA PARTNERSHIP DESIGNED TO RESPOND TO AN EMERGING THREAT IN TANZANIA: THE RAMPANT SPREAD OF ILLICIT ACTIVITY ON SOCIAL MEDIA PLATFORMS AND OTHER SURFACE WEBSITES.

2017 HPF AACR - FELICITY STREET REDEVELOPMENT

PURPOSE: TO SUPPORT THE DEVELOPMENT AND ADAPTATION OF THE NOVEL WHEN THE SEA TURNED TO SILVER BY GRACE LIN INTO A STAGE PRODUCTION.

PURPOSE OF THE AWARD IS TO SUPPORT MEDIA4YOUTH, A PROJECT TO FOSTER INCLUSION OF YOUTH VIEWS IN THE MEDIA.

PURPOSE OF THE AWARD IS TO SUPPORT PROJECT YOU HAVE RIGHT TO KNOW.

THE PURPOSE OF THIS AWARD IS TO CONTRIBUTE TO FOSTERING A CULTURE OF TOLERANCE AND INCLUSION OF IMMIGRANTS IN SLOVAKIA THROUGH CREATING A ROAD MAP AND DEVELOPING CONSULTANCY MECHANISMS FOR MUNICIPALITIES.

TO SUPPORT GENERAL OPERATING COSTS IN RESPONSE TO THE COVID-19 PANDEMIC.

THE PROJECT'S AIM IS TO DEVELOP AND EVALUATE SERVICES FOR CHILDREN AND PARENTS THAT WOULD FACILITATE SUCCESSFUL DESEGREGATION IN SCHOOLS IN ZILINA.

PURPOSE: TO SUPPORT ARTIST AND CREATIVE TEAM FEES FOR THE DEVELOPMENT AND PRESENTATION OF A PRODUCTION CREATED THROUGH SYNCHRONICITY THEATRE'S WOMAN'S WORK PROJECT.

TO SUPPORT THE WORLD PREMIERE OF HANDS OF COLOR A NEW PLAY BY KIMBERLY MONKS AT SYNCHROCITY THEATRE.

TO SUPPORT THE WORLD PREMIERE OF "BEYOND REASONABLE DOUBT: THE TROY DAVIS PROJECT," BY LEE NOWELL.

TO SUPPORT THE DEVELOPMENT OF "BEYOND REASONABLE DOUBT: THE TROY DAVIS PROJECT."

AFFIRMATIVE ACTION SUPPORT TO ROMANI UNIVERSITY STUDENTS TO HELP HIGH-ACHIEVING STUDENTS MAKE IT INTO AND THEN SUCCEED IN UNIVERSITIES.

SEC. 9007 REAP-RENEW ENERGY SYS GRANTS (MAN)

ASSISTANCE TO FIREFIGHTERS GRANT